🔗

Mappings

MONDO

MONDO:0016499 autoimmune autonomic ganglionopathy

MONDO exact match for Orphanet ORPHA:231457.

📘

Definitions

1

Orphanet acute pandysautonomia definition

A rare variant of Guillain-Barré syndrome characterized by acute post-ganglionic sympathetic and parasympathetic failure presenting several weeks after acute infection with gastrointestinal symptoms (abdominal pain, vomiting, constipation, diarrhea, gastroparesis, ileus), orthostatic hypotension, erectile dysfunction, urinary frequency, urgency or retention, vasomotor instability with acrocyanosis and reduced salivation, lacrimation and sweating.

OTHER

Show evidence (1 reference)

ORPHA:231457 SUPPORT Other

"A rare variant of Guillain-Barré syndrome characterized by acute post-ganglionic sympathetic and parasympathetic failure"

Orphanet provides the disease definition linked to MONDO:0016499.

◆

Subtypes

3

gAChRalpha3-positive AAG

Seropositive AAG subgroup with autoantibodies against the ganglionic acetylcholine receptor alpha3 subunit.

Show evidence (1 reference)

PMID:31924415 SUPPORT Human Clinical

"including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."

The 179-patient cohort defines the alpha3-positive serologic subgroup.

gAChRbeta4-positive AAG

Seropositive AAG subgroup with autoantibodies against the ganglionic acetylcholine receptor beta4 subunit.

Show evidence (1 reference)

PMID:31924415 SUPPORT Human Clinical

"including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."

The 179-patient cohort defines the beta4-positive serologic subgroup.

gAChRalpha3/gAChRbeta4 double-positive AAG

Seropositive AAG subgroup with both alpha3 and beta4 ganglionic acetylcholine receptor autoantibodies.

Show evidence (1 reference)

PMID:31924415 SUPPORT Human Clinical

"including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."

The 179-patient cohort identifies double antibody-positive patients as a distinct serologic subgroup.

⚙

Pathophysiology

3

Ganglionic Acetylcholine Receptor Autoantibodies

Circulating autoantibodies against ganglionic nicotinic acetylcholine receptors, especially alpha3-containing receptors in autonomic ganglia, identify a seropositive subset and correlate with autonomic failure severity.

autonomic neuron link

humoral immune response mediated by circulating immunoglobulin link ↑ INCREASED

autonomic ganglion link

Downstream

Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction Patient IgG and anti-alpha3 antibodies can reduce functional ganglionic AChR current and surface receptor availability.

Show evidence (3 references)

PMID:10995864 SUPPORT Human Clinical

"Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia."

This foundational patient-serology study identifies ganglionic acetylcholine receptor antibodies as markers of autoimmune autonomic neuropathy.

PMID:31761837 SUPPORT Human Clinical

"Approximately half of the patients with AAG have the autoantibodies against the neuronal nicotinic acetylcholine receptor (AChR) in autonomic ganglia."

This review summarizes the approximate seropositive fraction and target receptor location.

PMID:31924415 SUPPORT Human Clinical

"A total of 179 patients tested positive for antibodies, including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."

This large seropositive cohort supports alpha3 and beta4 ganglionic AChR antibody subgroups.

Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction

Patient IgG can block or modulate ganglionic acetylcholine receptors, including internalization of surface receptors, reducing postsynaptic nicotinic receptor function at autonomic ganglia.

autonomic neuron link

acetylcholine receptor signaling pathway link ↓ DECREASED cholinergic synaptic transmission link ↓ DECREASED

acetylcholine receptor activity link ↓ DECREASED

autonomic ganglion link

Downstream

Postganglionic Sympathetic and Parasympathetic Failure Reduced ganglionic cholinergic signaling disrupts sympathetic, parasympathetic, and enteric autonomic outflow.

Show evidence (3 references)

PMID:17536048 SUPPORT In Vitro

"IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect."

Patient IgG directly reduced ganglionic AChR current in a human cell assay.

PMID:23313381 SUPPORT In Vitro

"These data support the hypothesis that anti-α3 subunit autoantibody induces internalization of cell-surface nAChRs and thereby impairs synaptic transmission."

Cell-based evidence supports receptor internalization as a mechanism for impaired transmission.

PMID:18951069 SUPPORT Other

"AAG is an antibody-mediated neurological disorder. Antibodies from patients with AAG inhibit ganglionic AChR currents and impair transmission in autonomic ganglia."

This mechanistic review links patient antibodies to impaired ganglionic AChR currents and autonomic ganglion transmission.

Postganglionic Sympathetic and Parasympathetic Failure

Failure of postganglionic sympathetic and parasympathetic autonomic output links autonomic ganglion dysfunction to cardiovascular, sudomotor, secretomotor, urinary, gastrointestinal, and pupillary manifestations.

autonomic neuron link

cholinergic synaptic transmission link ↓ DECREASED

autonomic ganglion link

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"acute post-ganglionic sympathetic and parasympathetic failure"

The Orphanet definition directly supports postganglionic sympathetic and parasympathetic failure as the defining mechanism.

PMID:18951069 SUPPORT Other

"Patients with high levels of ganglionic AChR antibodies typically present with rapid onset of severe autonomic failure, with orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."

This review connects high ganglionic AChR antibody levels with the core autonomic failure phenotype.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Cardiovascular 1

Reduced Lacrimation Keratoconjunctivitis sicca (HP:0001097)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"reduced salivation, lacrimation and sweating"

Orphanet lists reduced lacrimation among secretomotor manifestations.

PMID:18268189 SUPPORT Human Clinical

"Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."

This case-series abstract includes dry eyes among AAG autonomic-failure symptoms.

Genitourinary 1

Urinary Retention Urinary retention (HP:0000016)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"urinary frequency, urgency or retention"

Orphanet lists urinary retention as part of the autonomic urinary phenotype.

PMID:18268189 SUPPORT Human Clinical

"Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."

This prospective case-series abstract includes bladder hypomotility among AAG autonomic-failure symptoms.

Head and Neck 1

Reduced Salivation Xerostomia (HP:0000217)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"reduced salivation, lacrimation and sweating"

Orphanet lists reduced salivation among secretomotor manifestations.

PMID:18268189 SUPPORT Human Clinical

"Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."

This case-series abstract includes dry mouth among AAG autonomic-failure symptoms.

Integument 1

Acrocyanosis Acrocyanosis (HP:0001063)

Show evidence (1 reference)

ORPHA:231457 SUPPORT Other

"vasomotor instability with acrocyanosis"

Orphanet lists acrocyanosis with vasomotor instability.

Nervous System 1

Sensory Disturbance Sensory neuropathy (HP:0000763)

Show evidence (1 reference)

PMID:31924415 SUPPORT Human Clinical

"Extra-autonomic manifestations including sensory disturbance, central nervous system involvement, endocrine disorders, autoimmune diseases, and tumours were present in 118 patients (83%)."

This large seropositive AAG cohort identifies sensory disturbance among extra-autonomic manifestations present in most patients.

Other 5

Orthostatic Hypotension Orthostatic hypotension due to autonomic dysfunction (HP:0004926)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"orthostatic hypotension"

Orphanet lists orthostatic hypotension among acute pandysautonomia manifestations.

PMID:18951069 SUPPORT Other

"rapid onset of severe autonomic failure, with orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."

This review places orthostatic hypotension among the core manifestations associated with high ganglionic AChR antibody levels.

Gastrointestinal Dysmotility Gastrointestinal dysmotility (HP:0002579)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"gastrointestinal symptoms (abdominal pain, vomiting, constipation, diarrhea, gastroparesis, ileus)"

Orphanet describes a broad gastrointestinal dysautonomia phenotype including constipation.

PMID:34249013 SUPPORT Other

"most commonly leading to orthostatic hypotension, gastrointestinal dysmotility, degrees of anhidrosis"

This AAG assay paper summarizes gastrointestinal dysmotility as a common clinical manifestation.

Gastroparesis Gastroparesis (HP:0002578)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"gastroparesis"

Orphanet lists gastroparesis among gastrointestinal symptoms.

PMID:12773498 SUPPORT Model Organism

"severe panautonomic failure with fixed mydriasis, gastroparesis, dry eyes, impaired heart rate variability, hypotension, and low plasma catecholamines."

The experimental autoimmune autonomic neuropathy model recapitulates gastroparesis as part of panautonomic failure.

Reduced Sweating Anhidrosis (HP:0000970)

Show evidence (2 references)

ORPHA:231457 SUPPORT Other

"reduced salivation, lacrimation and sweating"

Orphanet lists reduced sweating among secretomotor/sudomotor manifestations.

PMID:18951069 SUPPORT Other

"orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."

This review identifies anhidrosis as part of the antibody-associated autonomic failure syndrome.

Abnormal Pupillary Light Reflex Abnormal pupillary light reflex (HP:0007695)

Show evidence (2 references)

PMID:18951069 SUPPORT Other

"Impaired pupillary light reflex is often seen."

This review identifies impaired pupillary light reflex as a common AAG manifestation.

PMID:18268189 SUPPORT Human Clinical

"Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."

This case-series abstract includes pupillary dysfunction among AAG autonomic-failure symptoms.

💊

Treatments

6

Immunotherapy

Action: immunotherapy Ontology label: immunotherapy procedure MAXO:0001002

Immune-directed therapy is used for seropositive and clinically compatible AAG, with objective cohort data showing improvement across autonomic symptom and testing domains after treatment.

Mechanism Target:

MODULATES Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction — Immunotherapy is intended to reduce the antibody-mediated autonomic transmission defect.

Show evidence (1 reference)

PMID:31093868 SUPPORT Other

"antibodies against the ganglionic nicotinic acetylcholine receptor impair autonomic transmission, causing autonomic failure, which responds to immunotherapy."

This review links AAG's antibody-mediated transmission defect with clinical response to immunotherapy.

Show evidence (2 references)

PMID:31093868 SUPPORT Other

"autoimmune autonomic ganglionopathy (AAG), in which antibodies against the ganglionic nicotinic acetylcholine receptor impair autonomic transmission, causing autonomic failure, which responds to immunotherapy."

This review summarizes immunotherapy-responsive AAG as the classic autoimmune autonomic ganglionopathy.

PMID:33438240 SUPPORT Human Clinical

"After immunotherapy, there were significant improvements in orthostatic intolerance ratio"

This seropositive AAG cohort provides objective autonomic biomarker evidence of improvement after immunotherapy.

Intravenous Immunoglobulin

Action: Intravenous Immunoglobulin Therapy NCIT:C121331

IVIG is used as an immunomodulatory therapy in AAG, often as initial therapy and sometimes as part of a longer combined immunotherapy plan.

Show evidence (1 reference)

PMID:19056323 SUPPORT Human Clinical

"Treatment with intravenous immunoglobulin (IVIG) or plasma exchange (PE) has been reported to be effective in single case reports and recent case series."

This treatment review summarizes human case-report and case-series experience with IVIG.

Plasma Exchange

Action: Plasmapheresis NCIT:C15304

Plasma exchange can acutely reduce circulating ganglionic AChR antibodies and improve autonomic signs, although sustained benefit may require combined immunosuppression.

Mechanism Target:

INHIBITS Ganglionic Acetylcholine Receptor Autoantibodies — Plasma exchange lowers circulating pathogenic antibody burden.

Show evidence (1 reference)

PMID:18268189 SUPPORT Human Clinical

"Mean antibody level was 7.92 nmol/L on combined immunosuppressive therapy alone and dropped to 0.5 nmol/L after plasmapheresis."

The case series directly shows lower antibody levels after plasmapheresis.

Show evidence (2 references)

PMID:18268189 SUPPORT Human Clinical

"In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."

Prospective case-series evidence supports combined immunosuppression plus plasmapheresis for sustained improvement.

PMID:19399547 SUPPORT Human Clinical

"In conclusion, total PLEX temporarily improved clinical and laboratory abnormalities in this patient with AAG."

A detailed case report supports temporary clinical and laboratory improvement after plasma exchange.

Prednisone

Action: Pharmacotherapy NCIT:C15986

Agent: prednisone ↗

Prednisone was used as part of combined maintenance immunosuppression with mycophenolate mofetil and plasma exchange for sustained clinical benefit.

Show evidence (1 reference)

PMID:18268189 SUPPORT Human Clinical

"In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."

The prospective case series supports prednisone as part of combined immunosuppressive therapy for sustained AAG improvement.

Mycophenolate Mofetil

Action: Pharmacotherapy NCIT:C15986

Agent: mycophenolate mofetil ↗

Mycophenolate mofetil was used with prednisone as maintenance immunosuppression alongside plasma exchange for sustained clinical benefit.

Show evidence (1 reference)

PMID:18268189 SUPPORT Human Clinical

"In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."

The prospective case series supports mycophenolate mofetil as part of combined immunosuppressive therapy for sustained AAG improvement.

Rituximab

Action: Pharmacotherapy NCIT:C15986

Agent: rituximab ↗

Rituximab is reported for refractory or relapsing AAG, targeting B-cell mediated autoantibody production after or alongside other immunotherapies.

Mechanism Target:

INHIBITS Ganglionic Acetylcholine Receptor Autoantibodies — CD20+ B-cell depletion may reduce pathogenic antibody production.

Show evidence (1 reference)

PMID:19399547 SUPPORT Human Clinical

"Rituximab resulted in minor decreases in antibody level and persistent symptomatic improvement over at least several months."

This AAG case report links rituximab to lower antibody levels and sustained symptomatic improvement.

Show evidence (1 reference)

PMID:19399547 SUPPORT Human Clinical

"Rituximab resulted in minor decreases in antibody level and persistent symptomatic improvement over at least several months."

This case report supports rituximab as a later-line immunotherapy option.

🔬

Biochemical Markers

1

Serum Ganglionic Acetylcholine Receptor Antibodies (Positive in subset)

Show evidence (3 references)

PMID:31761837 SUPPORT Human Clinical

"Approximately half of the patients with AAG have the autoantibodies against the neuronal nicotinic acetylcholine receptor (AChR) in autonomic ganglia."

This review supports serum ganglionic AChR antibody positivity in about half of patients.

PMID:10995864 SUPPORT Human Clinical

"Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent)"

This original serology cohort supports ganglionic receptor antibody detection in autoimmune autonomic neuropathy.

PMID:31924415 SUPPORT Human Clinical

"A total of 179 patients tested positive for antibodies, including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."

This large Japanese cohort documents alpha3, beta4, and double-positive gAChR antibody groups.

🔬

Clinical Trials

1

NCT01522235 PHASE_II COMPLETED

Completed phase 2/3 randomized, double-blind placebo-controlled trial evaluating intravenous immunoglobulin for orthostatic hypotension symptoms and quality of life in AAG.

Target Phenotypes: Orthostatic hypotension due to autonomic dysfunction ↗

Show evidence (1 reference)

clinicaltrials:NCT01522235 SUPPORT Human Clinical

"helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life"

ClinicalTrials.gov describes the IVIG trial as evaluating orthostatic hypotension symptoms and quality of life in AAG.

{ }

Source YAML

click to show

name: Autoimmune Autonomic Ganglionopathy
creation_date: "2026-05-16T20:19:02Z"
updated_date: "2026-05-17T06:12:22Z"
category: Autoimmune
synonyms:
- AAG
- Acute pandysautonomia
- Acute panautonomic Guillain-Barre syndrome
- Acute panautonomic neuropathy
- Autoimmune autonomic neuropathy
description: >-
  Autoimmune autonomic ganglionopathy is an acquired immune-mediated autonomic
  neuropathy in which ganglionic acetylcholine receptor autoantibodies, present
  in a clinically important subset, impair cholinergic synaptic transmission in
  autonomic ganglia. The resulting postganglionic sympathetic,
  parasympathetic, and enteric failure causes diffuse pandysautonomia,
  including orthostatic hypotension, gastrointestinal dysmotility, urinary
  dysfunction, sweating abnormalities, pupillary dysfunction, and reduced
  salivary and lacrimal secretion. Orphanet and MONDO align the disorder with
  acute pandysautonomia, a rare Guillain-Barre syndrome variant.
disease_term:
  preferred_term: autoimmune autonomic ganglionopathy
  term:
    id: MONDO:0016499
    label: autoimmune autonomic ganglionopathy
parents:
- Guillain-Barre Syndrome
- Autoimmune Disease
- Neurological Disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0016499
      label: autoimmune autonomic ganglionopathy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO exact match for Orphanet ORPHA:231457.
definitions:
- name: Orphanet acute pandysautonomia definition
  definition_type: OTHER
  description: >-
    A rare variant of Guillain-Barré syndrome characterized by acute
    post-ganglionic sympathetic and parasympathetic failure presenting several
    weeks after acute infection with gastrointestinal symptoms (abdominal pain,
    vomiting, constipation, diarrhea, gastroparesis, ileus), orthostatic
    hypotension, erectile dysfunction, urinary frequency, urgency or retention,
    vasomotor instability with acrocyanosis and reduced salivation, lacrimation
    and sweating.
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare variant of Guillain-Barré syndrome characterized by acute post-ganglionic sympathetic and parasympathetic failure"
    explanation: Orphanet provides the disease definition linked to MONDO:0016499.
has_subtypes:
- name: Alpha3-positive AAG
  display_name: gAChRalpha3-positive AAG
  description: >-
    Seropositive AAG subgroup with autoantibodies against the ganglionic
    acetylcholine receptor alpha3 subunit.
  evidence:
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."
    explanation: The 179-patient cohort defines the alpha3-positive serologic subgroup.
- name: Beta4-positive AAG
  display_name: gAChRbeta4-positive AAG
  description: >-
    Seropositive AAG subgroup with autoantibodies against the ganglionic
    acetylcholine receptor beta4 subunit.
  evidence:
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."
    explanation: The 179-patient cohort defines the beta4-positive serologic subgroup.
- name: Double-positive AAG
  display_name: gAChRalpha3/gAChRbeta4 double-positive AAG
  description: >-
    Seropositive AAG subgroup with both alpha3 and beta4 ganglionic
    acetylcholine receptor autoantibodies.
  evidence:
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."
    explanation: The 179-patient cohort identifies double antibody-positive patients as a distinct serologic subgroup.
progression:
- phase: Acute or subacute pandysautonomia
  age_range: All ages
  notes: >-
    Orphanet records all ages as possible onset and describes presentation
    several weeks after an acute infection.
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet records all ages as the onset category for acute pandysautonomia.
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "presenting several weeks after acute infection"
    explanation: Orphanet describes a post-infectious interval before clinical presentation.
pathophysiology:
- name: Ganglionic Acetylcholine Receptor Autoantibodies
  description: >-
    Circulating autoantibodies against ganglionic nicotinic acetylcholine
    receptors, especially alpha3-containing receptors in autonomic ganglia,
    identify a seropositive subset and correlate with autonomic failure
    severity.
  biological_processes:
  - preferred_term: humoral immune response mediated by circulating immunoglobulin
    term:
      id: GO:0002455
      label: humoral immune response mediated by circulating immunoglobulin
    modifier: INCREASED
  cell_types:
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  locations:
  - preferred_term: autonomic ganglion
    term:
      id: UBERON:0001805
      label: autonomic ganglion
  evidence:
  - reference: PMID:10995864
    reference_title: "Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia."
    explanation: This foundational patient-serology study identifies ganglionic acetylcholine receptor antibodies as markers of autoimmune autonomic neuropathy.
  - reference: PMID:31761837
    reference_title: "[Autoimmune autonomic ganglionopathy]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately half of the patients with AAG have the autoantibodies against the neuronal nicotinic acetylcholine receptor (AChR) in autonomic ganglia."
    explanation: This review summarizes the approximate seropositive fraction and target receptor location.
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 179 patients tested positive for antibodies, including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."
    explanation: This large seropositive cohort supports alpha3 and beta4 ganglionic AChR antibody subgroups.
  downstream:
  - target: Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction
    causal_link_type: DIRECT
    description: Patient IgG and anti-alpha3 antibodies can reduce functional ganglionic AChR current and surface receptor availability.
    evidence:
    - reference: PMID:17536048
      reference_title: "Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect."
      explanation: Patient IgG directly reduced ganglionic AChR current, supporting a causal link from autoantibodies to receptor dysfunction.
- name: Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction
  description: >-
    Patient IgG can block or modulate ganglionic acetylcholine receptors,
    including internalization of surface receptors, reducing postsynaptic
    nicotinic receptor function at autonomic ganglia.
  molecular_functions:
  - preferred_term: acetylcholine receptor activity
    term:
      id: GO:0015464
      label: acetylcholine receptor activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: acetylcholine receptor signaling pathway
    term:
      id: GO:0095500
      label: acetylcholine receptor signaling pathway
    modifier: DECREASED
  - preferred_term: cholinergic synaptic transmission
    term:
      id: GO:0007271
      label: synaptic transmission, cholinergic
    modifier: DECREASED
  cell_types:
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  locations:
  - preferred_term: autonomic ganglion
    term:
      id: UBERON:0001805
      label: autonomic ganglion
  evidence:
  - reference: PMID:17536048
    reference_title: "Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect."
    explanation: Patient IgG directly reduced ganglionic AChR current in a human cell assay.
  - reference: PMID:23313381
    reference_title: "Autoantibody-induced internalization of nicotinic acetylcholine receptor α3 subunit exogenously expressed in human embryonic kidney cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These data support the hypothesis that anti-α3 subunit autoantibody induces internalization of cell-surface nAChRs and thereby impairs synaptic transmission."
    explanation: Cell-based evidence supports receptor internalization as a mechanism for impaired transmission.
  - reference: PMID:18951069
    reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "AAG is an antibody-mediated neurological disorder. Antibodies from patients with AAG inhibit ganglionic AChR currents and impair transmission in autonomic ganglia."
    explanation: This mechanistic review links patient antibodies to impaired ganglionic AChR currents and autonomic ganglion transmission.
  downstream:
  - target: Postganglionic Sympathetic and Parasympathetic Failure
    causal_link_type: DIRECT
    description: Reduced ganglionic cholinergic signaling disrupts sympathetic, parasympathetic, and enteric autonomic outflow.
    evidence:
    - reference: PMID:18951069
      reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Impaired cholinergic ganglionic synaptic transmission is one important cause of autonomic failure."
      explanation: This review directly supports the link from impaired ganglionic cholinergic signaling to autonomic failure.
- name: Postganglionic Sympathetic and Parasympathetic Failure
  description: >-
    Failure of postganglionic sympathetic and parasympathetic autonomic output
    links autonomic ganglion dysfunction to cardiovascular, sudomotor,
    secretomotor, urinary, gastrointestinal, and pupillary manifestations.
  biological_processes:
  - preferred_term: cholinergic synaptic transmission
    term:
      id: GO:0007271
      label: synaptic transmission, cholinergic
    modifier: DECREASED
  cell_types:
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  locations:
  - preferred_term: autonomic ganglion
    term:
      id: UBERON:0001805
      label: autonomic ganglion
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "acute post-ganglionic sympathetic and parasympathetic failure"
    explanation: The Orphanet definition directly supports postganglionic sympathetic and parasympathetic failure as the defining mechanism.
  - reference: PMID:18951069
    reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Patients with high levels of ganglionic AChR antibodies typically present with rapid onset of severe autonomic failure, with orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."
    explanation: This review connects high ganglionic AChR antibody levels with the core autonomic failure phenotype.
phenotypes:
- name: Orthostatic Hypotension
  category: Clinical
  description: Orthostatic blood-pressure failure caused by autonomic dysfunction.
  phenotype_term:
    preferred_term: Orthostatic hypotension due to autonomic dysfunction
    term:
      id: HP:0004926
      label: Orthostatic hypotension due to autonomic dysfunction
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "orthostatic hypotension"
    explanation: Orphanet lists orthostatic hypotension among acute pandysautonomia manifestations.
  - reference: PMID:18951069
    reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "rapid onset of severe autonomic failure, with orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."
    explanation: This review places orthostatic hypotension among the core manifestations associated with high ganglionic AChR antibody levels.
- name: Gastrointestinal Dysmotility
  category: Clinical
  description: >-
    Autonomic gastrointestinal involvement may include constipation, diarrhea,
    gastroparesis, abdominal pain, vomiting, and ileus.
  phenotype_term:
    preferred_term: Gastrointestinal dysmotility
    term:
      id: HP:0002579
      label: Gastrointestinal dysmotility
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "gastrointestinal symptoms (abdominal pain, vomiting, constipation, diarrhea, gastroparesis, ileus)"
    explanation: Orphanet describes a broad gastrointestinal dysautonomia phenotype including constipation.
  - reference: PMID:34249013
    reference_title: "A Flow Cytometric Assay to Detect Functional Ganglionic Acetylcholine Receptor Antibodies by Immunomodulation in Autoimmune Autonomic Ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "most commonly leading to orthostatic hypotension, gastrointestinal dysmotility, degrees of anhidrosis"
    explanation: This AAG assay paper summarizes gastrointestinal dysmotility as a common clinical manifestation.
- name: Gastroparesis
  category: Clinical
  description: Delayed gastric emptying from autonomic gastrointestinal dysfunction.
  phenotype_term:
    preferred_term: Gastroparesis
    term:
      id: HP:0002578
      label: Gastroparesis
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "gastroparesis"
    explanation: Orphanet lists gastroparesis among gastrointestinal symptoms.
  - reference: PMID:12773498
    reference_title: "Experimental autoimmune autonomic neuropathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "severe panautonomic failure with fixed mydriasis, gastroparesis, dry eyes, impaired heart rate variability, hypotension, and low plasma catecholamines."
    explanation: The experimental autoimmune autonomic neuropathy model recapitulates gastroparesis as part of panautonomic failure.
- name: Urinary Retention
  category: Clinical
  description: Autonomic bladder dysfunction can cause urinary retention.
  phenotype_term:
    preferred_term: Urinary retention
    term:
      id: HP:0000016
      label: Urinary retention
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "urinary frequency, urgency or retention"
    explanation: Orphanet lists urinary retention as part of the autonomic urinary phenotype.
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."
    explanation: This prospective case-series abstract includes bladder hypomotility among AAG autonomic-failure symptoms.
- name: Reduced Sweating
  category: Clinical
  description: Sudomotor failure may manifest as reduced or absent sweating.
  phenotype_term:
    preferred_term: Anhidrosis
    term:
      id: HP:0000970
      label: Anhidrosis
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "reduced salivation, lacrimation and sweating"
    explanation: Orphanet lists reduced sweating among secretomotor/sudomotor manifestations.
  - reference: PMID:18951069
    reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "orthostatic hypotension, gastrointestinal dysmotility, anhidrosis, bladder dysfunction and sicca symptoms."
    explanation: This review identifies anhidrosis as part of the antibody-associated autonomic failure syndrome.
- name: Reduced Salivation
  category: Clinical
  description: Secretomotor dysfunction may cause reduced salivation and dry mouth.
  phenotype_term:
    preferred_term: Xerostomia
    term:
      id: HP:0000217
      label: Xerostomia
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "reduced salivation, lacrimation and sweating"
    explanation: Orphanet lists reduced salivation among secretomotor manifestations.
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."
    explanation: This case-series abstract includes dry mouth among AAG autonomic-failure symptoms.
- name: Reduced Lacrimation
  category: Clinical
  description: Secretomotor dysfunction may reduce tear production and cause dry eyes.
  phenotype_term:
    preferred_term: Keratoconjunctivitis sicca
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "reduced salivation, lacrimation and sweating"
    explanation: Orphanet lists reduced lacrimation among secretomotor manifestations.
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."
    explanation: This case-series abstract includes dry eyes among AAG autonomic-failure symptoms.
- name: Acrocyanosis
  category: Clinical
  description: Vasomotor instability can manifest as acrocyanosis.
  phenotype_term:
    preferred_term: Acrocyanosis
    term:
      id: HP:0001063
      label: Acrocyanosis
  evidence:
  - reference: ORPHA:231457
    reference_title: "Acute pandysautonomia (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "vasomotor instability with acrocyanosis"
    explanation: Orphanet lists acrocyanosis with vasomotor instability.
- name: Abnormal Pupillary Light Reflex
  category: Clinical
  description: Pupillary parasympathetic involvement can impair the pupillary light reflex.
  phenotype_term:
    preferred_term: Abnormal pupillary light reflex
    term:
      id: HP:0007695
      label: Abnormal pupillary light reflex
  evidence:
  - reference: PMID:18951069
    reference_title: "Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Impaired pupillary light reflex is often seen."
    explanation: This review identifies impaired pupillary light reflex as a common AAG manifestation.
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients present with symptoms of autonomic failure, including syncope, orthostatic hypotension, bowel and bladder hypomotility, pupillary dysfunction, and dry mouth and eyes."
    explanation: This case-series abstract includes pupillary dysfunction among AAG autonomic-failure symptoms.
- name: Sensory Disturbance
  category: Neurological
  description: Extra-autonomic sensory involvement can occur in seropositive AAG.
  phenotype_term:
    preferred_term: Sensory neuropathy
    term:
      id: HP:0000763
      label: Sensory neuropathy
  evidence:
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Extra-autonomic manifestations including sensory disturbance, central nervous system involvement, endocrine disorders, autoimmune diseases, and tumours were present in 118 patients (83%)."
    explanation: This large seropositive AAG cohort identifies sensory disturbance among extra-autonomic manifestations present in most patients.
biochemical:
- name: Serum Ganglionic Acetylcholine Receptor Antibodies
  presence: Positive in subset
  notes: >-
    Seropositivity increases diagnostic confidence but absence of detectable
    ganglionic AChR antibodies does not exclude clinically compatible AAG.
  evidence:
  - reference: PMID:31761837
    reference_title: "[Autoimmune autonomic ganglionopathy]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately half of the patients with AAG have the autoantibodies against the neuronal nicotinic acetylcholine receptor (AChR) in autonomic ganglia."
    explanation: This review supports serum ganglionic AChR antibody positivity in about half of patients.
  - reference: PMID:10995864
    reference_title: "Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent)"
    explanation: This original serology cohort supports ganglionic receptor antibody detection in autoimmune autonomic neuropathy.
  - reference: PMID:31924415
    reference_title: "A comprehensive analysis of the clinical characteristics and laboratory features in 179 patients with autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 179 patients tested positive for antibodies, including 116 gAChRα3-positive, 13 gAChRβ4-positive, and 50 double antibody-positive patients."
    explanation: This large Japanese cohort documents alpha3, beta4, and double-positive gAChR antibody groups.
treatments:
- name: Immunotherapy
  description: >-
    Immune-directed therapy is used for seropositive and clinically compatible
    AAG, with objective cohort data showing improvement across autonomic
    symptom and testing domains after treatment.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: MAXO:0001002
      label: immunotherapy procedure
  target_mechanisms:
  - target: Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction
    treatment_effect: MODULATES
    description: Immunotherapy is intended to reduce the antibody-mediated autonomic transmission defect.
    evidence:
    - reference: PMID:31093868
      reference_title: "Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "antibodies against the ganglionic nicotinic acetylcholine receptor impair autonomic transmission, causing autonomic failure, which responds to immunotherapy."
      explanation: This review links AAG's antibody-mediated transmission defect with clinical response to immunotherapy.
  evidence:
  - reference: PMID:31093868
    reference_title: "Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "autoimmune autonomic ganglionopathy (AAG), in which antibodies against the ganglionic nicotinic acetylcholine receptor impair autonomic transmission, causing autonomic failure, which responds to immunotherapy."
    explanation: This review summarizes immunotherapy-responsive AAG as the classic autoimmune autonomic ganglionopathy.
  - reference: PMID:33438240
    reference_title: "Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After immunotherapy, there were significant improvements in orthostatic intolerance ratio"
    explanation: This seropositive AAG cohort provides objective autonomic biomarker evidence of improvement after immunotherapy.
- name: Intravenous Immunoglobulin
  description: >-
    IVIG is used as an immunomodulatory therapy in AAG, often as initial therapy
    and sometimes as part of a longer combined immunotherapy plan.
  treatment_term:
    preferred_term: Intravenous Immunoglobulin Therapy
    term:
      id: NCIT:C121331
      label: Intravenous Immunoglobulin Therapy
  evidence:
  - reference: PMID:19056323
    reference_title: "Immunotherapy for autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with intravenous immunoglobulin (IVIG) or plasma exchange (PE) has been reported to be effective in single case reports and recent case series."
    explanation: This treatment review summarizes human case-report and case-series experience with IVIG.
- name: Plasma Exchange
  description: >-
    Plasma exchange can acutely reduce circulating ganglionic AChR antibodies
    and improve autonomic signs, although sustained benefit may require combined
    immunosuppression.
  treatment_term:
    preferred_term: Plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  target_mechanisms:
  - target: Ganglionic Acetylcholine Receptor Autoantibodies
    treatment_effect: INHIBITS
    description: Plasma exchange lowers circulating pathogenic antibody burden.
    evidence:
    - reference: PMID:18268189
      reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mean antibody level was 7.92 nmol/L on combined immunosuppressive therapy alone and dropped to 0.5 nmol/L after plasmapheresis."
      explanation: The case series directly shows lower antibody levels after plasmapheresis.
  evidence:
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."
    explanation: Prospective case-series evidence supports combined immunosuppression plus plasmapheresis for sustained improvement.
  - reference: PMID:19399547
    reference_title: "Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In conclusion, total PLEX temporarily improved clinical and laboratory abnormalities in this patient with AAG."
    explanation: A detailed case report supports temporary clinical and laboratory improvement after plasma exchange.
- name: Prednisone
  description: >-
    Prednisone was used as part of combined maintenance immunosuppression with
    mycophenolate mofetil and plasma exchange for sustained clinical benefit.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisone
      term:
        id: CHEBI:8382
        label: prednisone
  evidence:
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."
    explanation: The prospective case series supports prednisone as part of combined immunosuppressive therapy for sustained AAG improvement.
- name: Mycophenolate Mofetil
  description: >-
    Mycophenolate mofetil was used with prednisone as maintenance
    immunosuppression alongside plasma exchange for sustained clinical benefit.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  evidence:
  - reference: PMID:18268189
    reference_title: "Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with autoimmune autonomic ganglionopathy, combining immunosuppressive medications prednisone and mycophenolate mofetil with plasmapheresis provides substantial and sustained clinical improvement that was not seen using either treatment alone."
    explanation: The prospective case series supports mycophenolate mofetil as part of combined immunosuppressive therapy for sustained AAG improvement.
- name: Rituximab
  description: >-
    Rituximab is reported for refractory or relapsing AAG, targeting B-cell
    mediated autoantibody production after or alongside other immunotherapies.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Ganglionic Acetylcholine Receptor Autoantibodies
    treatment_effect: INHIBITS
    description: CD20+ B-cell depletion may reduce pathogenic antibody production.
    evidence:
    - reference: PMID:19399547
      reference_title: "Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Rituximab resulted in minor decreases in antibody level and persistent symptomatic improvement over at least several months."
      explanation: This AAG case report links rituximab to lower antibody levels and sustained symptomatic improvement.
  evidence:
  - reference: PMID:19399547
    reference_title: "Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Rituximab resulted in minor decreases in antibody level and persistent symptomatic improvement over at least several months."
    explanation: This case report supports rituximab as a later-line immunotherapy option.
clinical_trials:
- name: NCT01522235
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Completed phase 2/3 randomized, double-blind placebo-controlled trial
    evaluating intravenous immunoglobulin for orthostatic hypotension symptoms
    and quality of life in AAG.
  target_phenotypes:
  - preferred_term: Orthostatic hypotension due to autonomic dysfunction
    term:
      id: HP:0004926
      label: Orthostatic hypotension due to autonomic dysfunction
  evidence:
  - reference: clinicaltrials:NCT01522235
    reference_title: "A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "helps to improve the symptoms of orthostatic hypotension (sudden fall in blood pressure when a person stands up) and quality of life"
    explanation: ClinicalTrials.gov describes the IVIG trial as evaluating orthostatic hypotension symptoms and quality of life in AAG.
datasets: []
references:
- reference: DOI:10.1016/b978-008045046-9.00625-2
  title: Autoimmune Autonomic Neuropathy
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1080/14737175.2018.1540304
  title: 'Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment'
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1212/wnl.0b013e3181a92b52
  title: Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1212/wnl.50.6.1806
  title: Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1002/ana.26018
  title: Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.1007/s10286-019-00611-1
  title: "Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances."
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings: []
- reference: DOI:10.3389/fneur.2024.1495205
  title: 'Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice'
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings:
  - statement: 'Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice'
    supporting_text: A great proportion of neuromuscular diseases are immune-mediated, included myasthenia gravis, Lambert-Eaton myasthenic syndrome, acute- and chronic-onset autoimmune neuropathies (anti-MAG neuropathy, multifocal motor neuropathy, Guillain-Barré syndromes, chronic inflammatory demyelinating polyradiculoneuropathy, CANDA and autoimmune nodopathies), autoimmune neuronopathies, peripheral nerve hyperexcitability syndromes and idiopathic inflammatory myopathies.
    evidence:
    - reference: DOI:10.3389/fneur.2024.1495205
      reference_title: 'Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: A great proportion of neuromuscular diseases are immune-mediated, included myasthenia gravis, Lambert-Eaton myasthenic syndrome, acute- and chronic-onset autoimmune neuropathies (anti-MAG neuropathy, multifocal motor neuropathy, Guillain-Barré syndromes, chronic inflammatory demyelinating polyradiculoneuropathy, CANDA and autoimmune nodopathies), autoimmune neuronopathies, peripheral nerve hyperexcitability syndromes and idiopathic inflammatory myopathies.
      explanation: Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.
- reference: DOI:10.3390/ijms25042296
  title: 'Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis'
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings:
  - statement: Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies.
    supporting_text: Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies.
    evidence:
    - reference: DOI:10.3390/ijms25042296
      reference_title: 'Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies.
      explanation: Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.
- reference: DOI:10.4103/aian.aian_394_24
  title: 'Decoding Autoimmune Autonomic Disorders: A Less-Recognized Overlap'
  found_in:
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-falcon.md
  - Autoimmune_Autonomic_Ganglionopathy-deep-research-cyberian-codex.md
  findings:
  - statement: Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways.
    supporting_text: Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways.
    evidence:
    - reference: DOI:10.4103/aian.aian_394_24
      reference_title: 'Decoding Autoimmune Autonomic Disorders: A Less-Recognized Overlap'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways.
      explanation: Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.

📚

References & Deep Research

References

9

DOI:10.1016/b978-008045046-9.00625-2

Autoimmune Autonomic Neuropathy

No top-level findings curated for this source.

DOI:10.1080/14737175.2018.1540304

Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment

No top-level findings curated for this source.

DOI:10.1212/wnl.0b013e3181a92b52

Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy

No top-level findings curated for this source.

DOI:10.1212/wnl.50.6.1806

Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes

No top-level findings curated for this source.

DOI:10.1002/ana.26018

Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.

No top-level findings curated for this source.

DOI:10.1007/s10286-019-00611-1

Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances.

No top-level findings curated for this source.

DOI:10.3389/fneur.2024.1495205

Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice

1 finding

Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice

"A great proportion of neuromuscular diseases are immune-mediated, included myasthenia gravis, Lambert-Eaton myasthenic syndrome, acute- and chronic-onset autoimmune neuropathies (anti-MAG neuropathy, multifocal motor neuropathy, Guillain-Barré syndromes, chronic inflammatory demyelinating..."

Show evidence (1 reference)

DOI:10.3389/fneur.2024.1495205 SUPPORT Other

"A great proportion of neuromuscular diseases are immune-mediated, included myasthenia gravis, Lambert-Eaton myasthenic syndrome, acute- and chronic-onset autoimmune neuropathies (anti-MAG neuropathy, multifocal motor neuropathy, Guillain-Barré syndromes, chronic inflammatory demyelinating..."

Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.

DOI:10.3390/ijms25042296

Autoimmune Autonomic Neuropathy: From Pathogenesis to Diagnosis

1 finding

Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies.

"Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies."

Show evidence (1 reference)

DOI:10.3390/ijms25042296 SUPPORT Human Clinical

"Autoimmune autonomic ganglionopathy (AAG) is a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies."

Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.

DOI:10.4103/aian.aian_394_24

Decoding Autoimmune Autonomic Disorders: A Less-Recognized Overlap

1 finding

Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways.

"Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways."

Show evidence (1 reference)

DOI:10.4103/aian.aian_394_24 SUPPORT Other

"Autoimmune autonomic disorders encompass a spectrum of disorders mediated by immune responses directed against the autonomic nervous system, including the peripheral and central autonomic pathways."

Deep research cited this publication as relevant literature for Autoimmune Autonomic Ganglionopathy.

Deep Research

2

Disorder ▸

Disorder

Name: Autoimmune Autonomic Ganglionopathy
Category: Autoimmune
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 58

Key Pathophysiology Nodes

Ganglionic Acetylcholine Receptor Autoantibodies
Antibody-Mediated Ganglionic Acetylcholine Receptor Dysfunction
Postganglionic Sympathetic and Parasympathetic Failure

Citation Inventory (for evidence mapping)

DOI:10.1002/ana.26018
DOI:10.1007/s10286-019-00611-1
DOI:10.1016/b978-008045046-9.00625-2
DOI:10.1080/14737175.2018.1540304
DOI:10.1212/wnl.0b013e3181a92b52
DOI:10.1212/wnl.50.6.1806
DOI:10.3389/fneur.2024.1495205
DOI:10.3390/ijms25042296
DOI:10.4103/aian.aian_394_24

Falcon ▸

Autoimmune Autonomic Ganglionopathy (AAG) — Comprehensive Disease Characteristics Report

Edison Scientific Literature 49 citations 2026-05-16T13:47:04.313482

Autoimmune Autonomic Ganglionopathy (AAG) — Comprehensive Disease Characteristics Report

Executive summary

Autoimmune autonomic ganglionopathy (AAG) is a rare, immune-mediated disorder of peripheral autonomic failure affecting sympathetic, parasympathetic, and enteric systems, classically presenting with subacute-onset diffuse dysautonomia (e.g., orthostatic hypotension, anhidrosis, severe gastrointestinal and bladder dysfunction). Roughly half of clinically suspected cases have serum autoantibodies against the ganglionic nicotinic acetylcholine receptor (gAChR; typically α3-containing receptors), and antibody titers correlate with autonomic severity; immunotherapy (plasma exchange, IVIg, corticosteroids and steroid-sparing immunosuppression) can lead to objective improvement in many patients, though controlled trial data remain very limited. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 2-3, koay2021multimodalbiomarkersquantify pages 1-8)

1. Disease information

1.1 Definition and current understanding

AAG is an immune-mediated disorder with prominent/selective involvement of the peripheral autonomic nervous system, producing generalized autonomic failure and often orthostatic hypotension, anhidrosis, and parasympathetic dysfunction. (iodice2009efficacyofimmunotherapy pages 1-3)
AAG is commonly described as “a disease of autonomic failure caused by ganglionic acetylcholine receptor (gAChR) autoantibodies” (direct abstract statement). (nakane2024autoimmuneautonomicneuropathy pages 11-12)

1.2 Synonyms / alternative names

Commonly used terms in the literature include: - Autoimmune autonomic ganglionopathy (AAG) (nakane2024autoimmuneautonomicneuropathy pages 11-12, iodice2009efficacyofimmunotherapy pages 1-3) - Autoimmune autonomic neuropathy (umbrella term often including AAG) (nakane2024autoimmuneautonomicneuropathy pages 11-12) - Subacute panautonomic failure / subacute autonomic neuropathy (historical discovery context for ganglionic nAChR antibodies) (vernino1998neuronalnicotinicach pages 4-6, vernino1998neuronalnicotinicach pages 3-4)

1.3 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

In the evidence retrieved for this run, explicit OMIM/Orphanet/ICD-10/ICD-11/MeSH/MONDO identifiers were not present in accessible full text excerpts; this entry should be completed by querying those dedicated ontology resources directly. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2)

1.4 Evidence sources

The characterization below is derived from: - Aggregated disease-level clinical cohorts and reviews (e.g., Japanese cohort n=80; seropositive cohort n=13) (nakane2018autoimmuneautonomicganglionopathy pages 6-8, koay2021multimodalbiomarkersquantify pages 1-8) - Primary discovery and pathophysiology studies (Neurology 1998 discovery of neuronal/ganglionic nAChR antibodies) (vernino1998neuronalnicotinicach pages 1-2, vernino1998neuronalnicotinicach pages 3-4) - Interventional/observational clinical evidence and trial registry information (Neurology 2009 immunotherapy case series; ClinicalTrials.gov NCT01522235) (iodice2009efficacyofimmunotherapy pages 1-3, NCT01522235 chunk 1)

2. Etiology

2.1 Primary causal factors (mechanistic)

Autoantibody-mediated ganglionic synaptic failure - The principal autoantigen is the ganglionic nicotinic acetylcholine receptor (gAChR), typically α3-containing receptors (often α3β4). Patient antibodies bind α3 and can reduce receptor currents in vitro, supporting pathogenicity. (golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 2-3) - A 2024 mechanistic synthesis proposes a three-step pathogenic model: (1) antibody binding, (2) antibody-driven internalization/degradation reducing receptor number, and (3) functional blockade. (nakane2024autoimmuneautonomicneuropathy pages 2-3) - In a 2024 clinical utility review, AAG antibodies are described as acting “by preventing post‑synaptic depolarization, thereby blocking autonomic neurotransmission.” (loser2024autoantibodiesinneuromuscular pages 13-15)

Seronegative disease and heterogeneity - About ~50% of suspected AAG may be seronegative, and some evidence suggests possible antibody- vs cell-mediated subtypes, including steroid-responsive but IVIg/PLEX/rituximab-poorly responsive subsets. (mohapatra2024decodingautoimmuneautonomic pages 4-5, golden2019autoimmuneautonomicneuropathies pages 3-5)

2.2 Risk factors

Robust genetic susceptibility loci or causal germline variants were not identified in the retrieved evidence; AAG is primarily treated as an acquired autoimmune condition. (golden2019autoimmuneautonomicneuropathies pages 1-2)
Autoimmune comorbidity is common. In a seropositive cohort (n=13), 8/13 (62%) had other autoimmune diseases (e.g., hypothyroidism, inflammatory bowel disease, Addison’s, pernicious anemia). (koay2021multimodalbiomarkersquantify pages 8-13)
Antecedent infection or events are reported in subsets (see Temporal Development). (nakane2018autoimmuneautonomicganglionopathy pages 6-8, koay2021multimodalbiomarkersquantify pages 8-13)

2.3 Protective factors / gene–environment interactions

No protective genetic variants or specific gene–environment interaction evidence was present in the retrieved set; this remains a knowledge gap. (golden2019autoimmuneautonomicneuropathies pages 1-2)

3. Phenotypes

3.1 Core clinical phenotype (multi-domain autonomic failure)

AAG reflects diffuse autonomic failure across sympathetic, parasympathetic, and enteric domains. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2)

Common features and frequencies (cohort evidence) - Japanese seropositive cohort (n=80): - Orthostatic hypotension: 64/80 (80%) - Lower GI symptoms: 59/80 (74%) - Pupillary dysfunction: 21/80 (26%) - Sensory disturbance (dysesthesia/numbness): 37/80 (46%) - Extra-autonomic involvement overall: 67/80 (84%) - Gradual onset predominant: 62/80 (78%) - Antecedent events: 13/80 (16%) (nakane2018autoimmuneautonomicganglionopathy pages 6-8)

Seropositive multimodal cohort (n=13):
Impaired pupillary light constriction: 12/13 (92%); cholinergic supersensitivity in tested patients
Postganglionic sudomotor dysfunction: 7/8 (88%)
Urinary retention: 9/11 (82%); catheterisation needed 5/13 (38%)
Xerophthalmia (reduced lacrimation): 9/11 (82%); xerostomia: 6/8 (75%)
31% had antecedent infections; 15% antecedent surgery (koay2021multimodalbiomarkersquantify pages 13-17, koay2021multimodalbiomarkersquantify pages 8-13, koay2021multimodalbiomarkersquantify pages 1-8)

3.2 Suggested HPO terms (non-exhaustive; map to patient-level data when available)

Orthostatic hypotension (HP:0001278)
Autonomic dysfunction (HP:0004398)
Anhidrosis / hypohidrosis (HP:0000970 / HP:0000966)
Urinary retention / neurogenic bladder (HP:0000016 / HP:0000010)
Gastrointestinal dysmotility / constipation (HP:0002574 / HP:0002019)
Xerostomia / keratoconjunctivitis sicca (HP:0000217 / HP:0001097)
Abnormal pupillary light reflex / mydriasis (HP:0000615 / HP:0000611)
Sensory neuropathy / paresthesia (HP:0000763 / HP:0003401)

(nakane2018autoimmuneautonomicganglionopathy pages 6-8, koay2021multimodalbiomarkersquantify pages 1-8)

3.3 Quality of life impact

Quantitative symptom and QoL instruments are used in AAG cohorts, including COMPASS-31 and SF-36. In one seropositive cohort (n=13), immunotherapy improved COMPASS-31 scores (total 52 → 17, P=.03) and SF-36 physical function (example data in figures), consistent with clinically meaningful functional improvement. (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify pages 17-21)

4. Genetic / molecular information

4.1 Causal genes

AAG is not primarily described as a Mendelian genetic disorder in retrieved evidence. However, the target receptor comprises subunits including α3 and typically β4; these correspond to receptor subunit genes (e.g., CHRNA3, CHRNB4), but the disease mechanism is autoimmune rather than inherited mutation-based in the cited cohorts/reviews. (golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 2-3)

4.2 Pathogenic “variants”

Not applicable as germline pathogenic variants were not implicated as causal in the retrieved clinical literature. (golden2019autoimmuneautonomicneuropathies pages 1-2)

4.3 Epigenetics / modifiers

Not addressed in retrieved evidence.

5. Environmental information

5.1 Infectious or other triggers

Antecedent infections/events are reported in subsets of cohorts (e.g., 31% antecedent infections in a seropositive cohort; 16% antecedent events in a Japanese cohort). (koay2021multimodalbiomarkersquantify pages 8-13, nakane2018autoimmuneautonomicganglionopathy pages 6-8)

6. Mechanism / pathophysiology

6.1 Causal chain (antibody-mediated archetype)

1) Immune tolerance break (often idiopathic; sometimes paraneoplastic context in early discovery cohorts) with production of antibodies to ganglionic nAChR (α3-containing receptor). (vernino1998neuronalnicotinicach pages 4-6, golden2019autoimmuneautonomicneuropathies pages 1-2) 2) Antibody binding to extracellular receptor epitopes, with receptor internalization/degradation and functional blockade, reducing ganglionic synaptic transmission. (nakane2024autoimmuneautonomicneuropathy pages 2-3, nakane2018autoimmuneautonomicganglionopathy pages 3-5) 3) Downstream failure of autonomic output across multiple organs (cardiovascular, sudomotor, secretomotor, GI, bladder, pupillary systems), producing “pandysautonomia.” (iodice2009efficacyofimmunotherapy pages 1-3, koay2021multimodalbiomarkersquantify pages 1-8)

6.2 Upstream vs downstream processes

Upstream: autoantibody generation; in some patients, possibly alternative immune effector mechanisms (cell-mediated) in seronegative disease. (mohapatra2024decodingautoimmuneautonomic pages 4-5, golden2019autoimmuneautonomicneuropathies pages 3-5)
Downstream: postganglionic sympathetic and parasympathetic failure; reduced catecholamine release; end-organ dysfunction (e.g., impaired sweating, impaired lacrimation). (nakane2024autoimmuneautonomicneuropathy pages 11-12, koay2021multimodalbiomarkersquantify pages 1-8)

6.3 Cell types and GO / CL suggestions

Cell types (CL) – suggested: - Autonomic neuron (sympathetic neuron; parasympathetic neuron) - Postganglionic sympathetic neuron - Postganglionic parasympathetic neuron

Biological processes (GO) – suggested: - Chemical synaptic transmission, cholinergic - Autonomic nervous system development / regulation of autonomic nervous system - Regulation of blood pressure - Regulation of gastrointestinal motility - Regulation of sweating

(These align with receptor localization and physiological deficits described in cohorts and mechanistic studies.) (golden2019autoimmuneautonomicneuropathies pages 1-2, koay2021multimodalbiomarkersquantify pages 1-8)

6.4 Molecular profiling / multi-omics

No transcriptomic/proteomic/metabolomic signatures were reported in the retrieved evidence.

7. Anatomical structures affected

7.1 Organ and system level

Primary system: peripheral autonomic nervous system (autonomic ganglia and postganglionic fibers). (golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 11-12) Secondary/target organs include: - Cardiovascular system (orthostatic hypotension) (nakane2018autoimmuneautonomicganglionopathy pages 6-8) - Sweat glands (anhidrosis/hypohidrosis) (koay2021multimodalbiomarkersquantify pages 1-8) - Exocrine glands (lacrimal/salivary; sicca) (koay2021multimodalbiomarkersquantify pages 1-8, golden2019autoimmuneautonomicneuropathies pages 1-2) - GI tract (dysmotility) (nakane2018autoimmuneautonomicganglionopathy pages 6-8) - Urinary tract (neurogenic bladder/retention) (koay2021multimodalbiomarkersquantify pages 13-17) - Eye (pupil dysfunction) (koay2021multimodalbiomarkersquantify pages 13-17)

UBERON suggestions: - Autonomic ganglion; sympathetic ganglion; parasympathetic ganglion - Heart; gastrointestinal tract; urinary bladder; sweat gland; lacrimal gland; salivary gland; iris/pupil

7.2 Subcellular / receptor localization

Key molecular site: postsynaptic ganglionic nicotinic ACh receptor at autonomic ganglionic synapses. (vernino1998neuronalnicotinicach pages 4-6, loser2024autoantibodiesinneuromuscular pages 13-15)

8. Temporal development

8.1 Onset

Onset can be acute/subacute or gradual; one cohort defined subacute as peak within 3 months and found gradual onset predominated in seropositive patients. (nakane2018autoimmuneautonomicganglionopathy pages 6-8)

8.2 Course and progression

Spontaneous improvement occurs in ~one-third of patients but is often incomplete. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2)
Chronic phenotypes may resemble pure autonomic failure and can represent about half of seropositive patients in review-level synthesis. (golden2019autoimmuneautonomicneuropathies pages 1-2)

9. Inheritance and population

9.1 Epidemiology

AAG is consistently described as rare; specific population prevalence/incidence rates were not identified in the retrieved evidence. (golden2019autoimmuneautonomicneuropathies pages 1-2)

9.2 Demographics

Review synthesis: mean ages ~45–61 with ~2:1 female predominance. (golden2019autoimmuneautonomicneuropathies pages 1-2)
Seropositive multimodal cohort: median age at onset 54 (IQR 31–63), 54% female. (koay2021multimodalbiomarkersquantify pages 8-13)

10. Diagnostics

10.1 Core diagnostic concept

Diagnosis is a combination of: 1) compatible clinical syndrome (diffuse autonomic failure) and 2) objective autonomic testing and 3) supportive biomarkers, especially gAChR antibodies, recognizing limited sensitivity and potential nonspecific low titers. (iodice2009efficacyofimmunotherapy pages 1-3, nakane2024autoimmuneautonomicneuropathy pages 11-12)

10.2 Antibody testing: assays and interpretation

2024 synthesis: gAChR antibody testing is “essential” but detection frequency “is not high,” and CBA or RIPA are recommended as the most accurate assays. (nakane2024autoimmuneautonomicneuropathy pages 11-12)
Threshold interpretation (RIA/RIPA): >1.0 nmol/L high specificity; 0.2–1.0 nmol/L moderate specificity; <0.2 nmol/L nonspecific; low-level positivity can occur in 2–4% of healthy individuals. (loser2024autoantibodiesinneuromuscular pages 12-13, mohapatra2024decodingautoimmuneautonomic pages 4-5)
Assay landscape includes RIPA/RIA, luciferase immunoprecipitation (LIPS), cell-based assays, immunomodulation assays, and flow cytometry; a 2024 review notes “there are no studies directly comparing the performance metrices of these antibody assays.” (mohapatra2024decodingautoimmuneautonomic pages 4-5)

10.3 Autonomic testing and ancillary diagnostics

Commonly used tests in cohorts/reviews include: - Head-up tilt / orthostatic vitals; Valsalva; heart-rate response to deep breathing - QSART / thermoregulatory sweat testing; plasma catecholamines (resting often reduced) - Schirmer (lacrimation) and Saxon (salivation) tests - Pupillometry / pharmacologic testing (pilocarpine supersensitivity) - Uroflowmetry and post-void residuals - CSF (protein elevation / albuminocytologic dissociation in a substantial minority) - Cardiac 123I-MIBG myocardial scintigraphy (often reduced uptake; may improve after immunotherapy) - Skin biopsy for small-fiber/autonomic denervation and recovery biomarkers (iodice2009efficacyofimmunotherapy pages 3-4, nakane2024autoimmuneautonomicneuropathy pages 11-12, koay2021multimodalbiomarkersquantify pages 1-8, nakane2018autoimmuneautonomicganglionopathy pages 9-10)

10.4 Differential diagnosis

Differentiation from acute autonomic sensory neuropathy (AASN), pure autonomic failure (PAF), POTS, chronic fatigue syndrome, and long COVID is emphasized, using nerve conduction studies/biopsy, MRI in selected cases, catecholamine patterns, and multimodal autonomic testing. (nakane2024autoimmuneautonomicneuropathy pages 11-12)

11. Outcome / prognosis

Spontaneous (often incomplete) improvement in ~one-third is described in clinical synthesis. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2)
Long-term recovery can be quantified by biomarker improvement; in a seropositive cohort (n=13) immunotherapy significantly improved orthostatic intolerance ratio, HRDB, pupillary constriction, saliva production and COMPASS-31. (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify media 639533be)
Mortality rates and life expectancy are not defined in the retrieved evidence; this remains a data gap.

12. Treatment

12.1 Immunotherapy (disease-modifying)

First-line approaches - Reviews commonly describe IVIg and plasma exchange (PLEX) as first-line antibody-directed therapies; corticosteroids are often used in combination. (golden2019autoimmuneautonomicneuropathies pages 5-6, mohapatra2024decodingautoimmuneautonomic pages 4-5, golden2019autoimmuneautonomicneuropathies pages 3-5) - In a Neurology case series (n=6; 4 seropositive, 2 seronegative), all 6 patients improved clinically after immunotherapy; sudomotor measures improved in 4. (iodice2009efficacyofimmunotherapy pages 1-3)

Evidence of objective biomarker response - In a seropositive multimodal cohort (n=13; 11 treated), immunotherapy improved key outcomes, e.g. orthostatic intolerance ratio 33.3 → 5.2 (P=.007), COMPASS-31 52 → 17 (P=.03), and pupillary constriction and salivary measures (cohort-level pre/post comparisons), supported by Figure 2 and Table 5. (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify media 639533be)

Maintenance / refractory therapy - Steroid-sparing agents (e.g., mycophenolate, azathioprine) and B-cell depletion (rituximab) have case-based/series-level support and are used for relapsing or refractory disease. (golden2019autoimmuneautonomicneuropathies pages 5-6, nakane2018autoimmuneautonomicganglionopathy pages 9-10) - A 2024 review notes heterogeneity: a subset can show strong steroid responses with poorer response to IVIg/PLEX/rituximab, consistent with possible cell-mediated forms. (mohapatra2024decodingautoimmuneautonomic pages 4-5)

12.2 Symptomatic/supportive care (real-world implementations)

Pressor/orthostatic therapies (e.g., midodrine, droxidopa) are used to manage neurogenic orthostatic hypotension in AAG-focused reviews. (nakane2018autoimmuneautonomicganglionopathy pages 9-10)
Organ-specific supportive care is routinely required (bowel regimen and prokinetic strategies for dysmotility; catheterization/urodynamic-guided care for retention; ocular/oral sicca management). (golden2019autoimmuneautonomicneuropathies pages 1-2, koay2021multimodalbiomarkersquantify pages 13-17)

12.3 Clinical trials

NCT01522235 (ClinicalTrials.gov): randomized, double-blind, placebo-controlled Phase 2/3 IVIg vs 5% albumin in seropositive AAG; enrollment 6; started Feb 2012; primary completion May 2014; completion Sep 2015; results first posted Jul 2, 2017. Primary endpoint: change in systolic BP during 60° tilt (ΔSBP) at 6 weeks; secondary endpoints included COMPASS, CASS, EQ-5D, orthostatic symptom questionnaire. Outcome numbers were not present in the retrieved excerpts. (NCT01522235 chunk 1, NCT01522235 chunk 2)
URL: https://clinicaltrials.gov/study/NCT01522235 (trial registry; dates from record in evidence). (NCT01522235 chunk 1)

12.4 Suggested MAXO terms (non-exhaustive)

Plasma exchange therapy
Intravenous immunoglobulin therapy
Systemic glucocorticoid therapy
B-cell depletion therapy (rituximab)
Mycophenolate mofetil therapy
Vasopressor therapy (for neurogenic orthostatic hypotension)

13. Prevention

No established primary prevention strategies were identified in the retrieved evidence; prevention is largely secondary/tertiary (early recognition and treatment to prevent complications of severe autonomic failure). (nakane2024autoimmuneautonomicneuropathy pages 11-12)

14. Other species / natural disease

Naturally occurring veterinary analogs were not identified in the retrieved evidence. (golden2019autoimmuneautonomicneuropathies pages 1-2)

15. Model organisms

Multiple experimental systems support the antibody-mediated model: - α3 nAChR subunit knockout mice: profound autonomic failure (bladder distention, GI dysmotility, absent pupillary reflexes; urinary retention and increased mortality in review synthesis). (golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2018autoimmuneautonomicganglionopathy pages 3-5) - Passive transfer models: transfer of patient IgG to mice reduces evoked EPSP amplitudes in autonomic ganglia; EPSPs can recover despite persistent antibodies (suggesting homeostatic plasticity). (nakane2024autoimmuneautonomicneuropathy pages 2-3) - Active immunization models: immunization against ganglionic AChR (including α3 subunit strategies) induces experimental autoimmune dysautonomia/autonomic neuropathy in rabbits and mice. (vernino2009autoimmuneautonomicneuropathy pages 2-4, nakane2024autoimmuneautonomicneuropathy pages 12-14)

Recent developments (prioritizing 2023–2024)

Diagnostics and assay technology

2024 review-level consensus: CBA and/or RIPA are preferred for gAChR antibody detection; low sensitivity and limited access motivate new assays and expansion to other autonomic receptor targets. (nakane2024autoimmuneautonomicneuropathy pages 11-12)
2024 assay landscape and evidence gap: multiple assay modalities exist, but head-to-head performance comparisons are lacking (“no studies directly comparing…”). (mohapatra2024decodingautoimmuneautonomic pages 4-5)

Phenotyping and biomarkers for treatment response

Multidomain quantitative biomarker panels (tilt-derived orthostatic intolerance ratio, pupillometry, sweat testing, secretomotor measures, COMPASS-31) are used to quantify response, with significant pre/post immunotherapy changes in seropositive cohorts, and are highlighted as practical tools for monitoring. (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify media 639533be)

Expert opinions / authoritative analysis (from reviews)

AAG is described as “rare” and clinically heterogeneous, with antibody titers and phenotypic distribution supporting a spectrum ranging from severe pan-dysautonomia to limited phenotypes, and with recognition of potentially distinct seronegative mechanisms. (golden2019autoimmuneautonomicneuropathies pages 1-2, mohapatra2024decodingautoimmuneautonomic pages 4-5)
Clinical interpretation of autoantibody tests should be contextualized because low titers can be nonspecific, and assay characteristics vary across platforms and laboratories. (loser2024autoantibodiesinneuromuscular pages 12-13, loser2024autoantibodiesinneuromuscular pages 13-15)

Key quantitative statistics (selected)

Seropositivity: ~50% of suspected AAG cases seropositive for gAChR antibodies. (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2)
Low-titer nonspecificity: <0.2 nmol/L can be nonspecific and seen in ~2–4% of healthy individuals. (mohapatra2024decodingautoimmuneautonomic pages 4-5)
Japanese cohort symptom frequencies: orthostatic hypotension 80%; lower GI 74%; sensory disturbance 46%; extra-autonomic features 84%. (nakane2018autoimmuneautonomicganglionopathy pages 6-8)
Seropositive cohort (n=13) domain frequencies: urinary retention 82% (9/11); impaired pupillary constriction 92% (12/13); reduced lacrimation 82% (9/11); postganglionic sudomotor dysfunction 88% (7/8). (koay2021multimodalbiomarkersquantify pages 13-17, koay2021multimodalbiomarkersquantify pages 1-8)
Immunotherapy response (seropositive cohort): orthostatic intolerance ratio 33.3→5.2 (P=.007); COMPASS-31 52→17 (P=.03). (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify media 639533be)

Evidence table (compact)

Item	Evidence/Numbers	Source (with DOI/URL when available)	Pub year
Definition	Rare immune-mediated disorder causing diffuse autonomic failure involving sympathetic, parasympathetic, and enteric systems; often considered an antibody-mediated autonomic ganglionopathy/ganglionopathy phenotype (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 2-3)	Iodice et al., Neurology doi:10.1212/WNL.0b013e3181a92b52 https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, Clin Auton Res doi:10.1007/s10286-019-00611-1 https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., Int J Mol Sci doi:10.3390/ijms25042296 https://doi.org/10.3390/ijms25042296	2009; 2019; 2024
Core autoantigen / autoantibody	Ganglionic nicotinic acetylcholine receptor (gAChR), especially α3-containing receptor; antibodies bind mainly α3 subunit, usually in α3β4 receptor complex (golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2024autoimmuneautonomicneuropathy pages 2-3, vernino1998neuronalnicotinicach pages 1-2)	Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.3390/ijms25042296; Vernino et al., Neurology doi:10.1212/WNL.50.6.1806 https://doi.org/10.1212/WNL.50.6.1806	2019; 2024; 1998
Pathogenic mechanism	Proposed 3-step model: antibody binding → receptor internalization/degradation → functional blockade; patient IgG reduces ganglionic AChR currents; passive transfer in mice reduces EPSPs (nakane2024autoimmuneautonomicneuropathy pages 2-3, golden2019autoimmuneautonomicneuropathies pages 1-2)	Nakane et al., https://doi.org/10.3390/ijms25042296; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1	2024; 2019
Seropositivity rate	About 50% of clinically suspected AAG patients are seropositive for gAChR antibodies; seronegative disease remains recognized (mohapatra2024decodingautoimmuneautonomic pages 4-5, iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2018autoimmuneautonomicganglionopathy pages 1-3)	Mohapatra et al., Ann Indian Acad Neurol doi:10.4103/aian.aian_394_24 https://doi.org/10.4103/aian.aian_394_24; Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2024; 2009; 2019; 2018
Antibody threshold: classic RIPA positivity	Upper lab limit reported as 0.05 nmol/L in one major clinical series; antibody-positive AAG defined at or above this threshold (iodice2009efficacyofimmunotherapy pages 3-4, golden2019autoimmuneautonomicneuropathies pages 3-5)	Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1	2009; 2019
Antibody titer interpretation	>0.20 nmol/L fairly specific for AAG; high titers correlate with more severe dysautonomia/cholinergic failure; ≥1.0 nmol/L associated with severe pan-dysautonomia; <0.2 nmol/L often nonspecific and seen in ~2%–4% of healthy people (golden2019autoimmuneautonomicneuropathies pages 3-5, mohapatra2024decodingautoimmuneautonomic pages 4-5)	Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Mohapatra et al., https://doi.org/10.4103/aian.aian_394_24	2019; 2024
LIPS assay thresholds	Anti-gAChRα3 A.I. cutoff 1.0: sensitivity 50.0%, specificity 100%; anti-gAChRβ4 A.I. cutoff 1.0: sensitivity 10.0%, specificity 100% (nakane2018autoimmuneautonomicganglionopathy pages 5-6)	Nakane et al., Expert Rev Neurother doi:10.1080/14737175.2018.1540304 https://doi.org/10.1080/14737175.2018.1540304	2018
Typical demographics	Middle age predominance; mean ages reported ~45–61 years with ~2:1 female predominance; in Koay cohort median onset 54 years, 54% female; in Japanese cohort mean age 60±18 years (43M/37F) (golden2019autoimmuneautonomicneuropathies pages 1-2, koay2021multimodalbiomarkersquantify pages 8-13, nakane2018autoimmuneautonomicganglionopathy pages 5-6)	Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Koay et al., Ann Neurol doi:10.1002/ana.26018 https://doi.org/10.1002/ana.26018; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2019; 2021; 2018
Onset / course	Often acute or subacute; spontaneous but usually incomplete recovery in ~one-third; in seropositive Japanese cohort gradual onset predominated 62/80 (78%), antecedent events 13/80 (16%) (iodice2009efficacyofimmunotherapy pages 1-3, golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2018autoimmuneautonomicganglionopathy pages 6-8, nakane2018autoimmuneautonomicganglionopathy pages 1-3)	Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2009; 2019; 2018
Common feature: orthostatic hypotension / intolerance	Most common presenting/autonomic feature; 64/80 (80%) in seropositive Japanese cohort; initial symptom in 50/80 (62.5%); all 13/13 in Koay cohort had cardiovascular autonomic failure with orthostatic hypotension (nakane2018autoimmuneautonomicganglionopathy pages 6-8, koay2021multimodalbiomarkersquantify pages 8-13)	Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018	2018; 2021
Common feature: lower GI dysmotility	Lower GI symptoms in 59/80 (74%) seropositive cases; GI dysfunction is a core cholinergic manifestation (nakane2018autoimmuneautonomicganglionopathy pages 6-8, golden2019autoimmuneautonomicneuropathies pages 1-2, nakane2018autoimmuneautonomicganglionopathy pages 9-10)	Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1	2018; 2019
Common feature: urinary dysfunction	Urinary retention 9/11 (82%); catheterisation required in 5/13 (38%); abnormal uroflowmetry in 6/8 (75%) in Koay cohort (koay2021multimodalbiomarkersquantify pages 13-17, koay2021multimodalbiomarkersquantify pages 1-8)	Koay et al., https://doi.org/10.1002/ana.26018	2021
Common feature: pupillary dysfunction	Pupillary dysfunction 21/80 (26%) in Japanese cohort; in Koay cohort impaired pupillary constriction 12/13 (92%), cholinergic supersensitivity in 5/5 tested, ptosis 4/13 (31%) (nakane2018autoimmuneautonomicganglionopathy pages 6-8, koay2021multimodalbiomarkersquantify pages 13-17, koay2021multimodalbiomarkersquantify pages 8-13)	Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018	2018; 2021
Common feature: secretomotor dysfunction	Reduced lacrimation 9/11 (82%), reduced salivary production 6/8 (75%), impaired sweat production 7/8 (88%) in Koay cohort; sicca/anhidrosis also emphasized in reviews (koay2021multimodalbiomarkersquantify pages 13-17, koay2021multimodalbiomarkersquantify pages 1-8, golden2019autoimmuneautonomicneuropathies pages 1-2)	Koay et al., https://doi.org/10.1002/ana.26018; Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1	2021; 2019
Extra-autonomic manifestations	Extra-autonomic involvement common: 67/80 (84%) in seropositive Japanese cohort; sensory disturbance/numbness 37/80 (46%); concurrent autoimmune disease in 25/80 (31%); tumors in 11/80 (14%); in Koay cohort other autoimmune diseases in 8/13 (62%) (nakane2018autoimmuneautonomicganglionopathy pages 6-8, nakane2018autoimmuneautonomicganglionopathy pages 8-9, koay2021multimodalbiomarkersquantify pages 8-13)	Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018	2018; 2021
Catecholamine / imaging biomarkers	Resting plasma catecholamines often low; in Koay cohort plasma noradrenaline mostly 100–200 pg/ml with absent tilt rise; reduced cardiac 123I-MIBG uptake in ~80% of Japanese AAG cohort, and uptake may improve after immunotherapy (nakane2024autoimmuneautonomicneuropathy pages 11-12, koay2021multimodalbiomarkersquantify pages 8-13, nakane2018autoimmuneautonomicganglionopathy pages 9-10)	Nakane et al., https://doi.org/10.3390/ijms25042296; Koay et al., https://doi.org/10.1002/ana.26018; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2024; 2021; 2018
CSF findings	Elevated CSF protein in 48% and albuminocytologic dissociation in 37% in review summary; another review cites albuminocytologic dissociation in ~40% (nakane2024autoimmuneautonomicneuropathy pages 11-12, mohapatra2024decodingautoimmuneautonomic pages 4-5)	Nakane et al., https://doi.org/10.3390/ijms25042296; Mohapatra et al., https://doi.org/10.4103/aian.aian_394_24	2024; 2024
Core diagnostic tests	History and time-course; autonomic reflex screen; head-up tilt; Valsalva; HR response to deep breathing; QSART/TST/sweat testing; plasma catecholamines; Schirmer/Saxon tests; pupillometry; uroflowmetry; GI motility studies; skin biopsy; 123I-MIBG scintigraphy; gAChR antibody testing by RIPA/CBA/LIPS (iodice2009efficacyofimmunotherapy pages 3-4, nakane2024autoimmuneautonomicneuropathy pages 11-12, nakane2018autoimmuneautonomicganglionopathy pages 9-10, koay2021multimodalbiomarkersquantify pages 8-13)	Iodice et al., https://doi.org/10.1212/WNL.0b013e3181a92b52; Nakane et al., https://doi.org/10.3390/ijms25042296; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304; Koay et al., https://doi.org/10.1002/ana.26018	2009; 2024; 2018; 2021
Preferred antibody assays	RIPA or live cell-based assay considered most accurate in recent review; LIPS also used with high specificity in Japanese studies (nakane2024autoimmuneautonomicneuropathy pages 11-12, nakane2018autoimmuneautonomicganglionopathy pages 5-6)	Nakane et al., https://doi.org/10.3390/ijms25042296; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2024; 2018
First-line immunotherapy	IVIG and plasma exchange generally regarded as first-line; corticosteroids commonly added/used in pulse regimens (golden2019autoimmuneautonomicneuropathies pages 5-6, nakane2018autoimmuneautonomicganglionopathy pages 9-10, nakane2018autoimmuneautonomicganglionopathy pages 1-3)	Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2019; 2018
Maintenance / refractory treatment	Prednisolone, azathioprine, mycophenolate mofetil, rituximab used for sustained control or refractory disease; evidence mainly case reports/series (golden2019autoimmuneautonomicneuropathies pages 5-6, nakane2018autoimmuneautonomicganglionopathy pages 9-10, golden2019autoimmuneautonomicneuropathies pages 3-5)	Golden & Vernino, https://doi.org/10.1007/s10286-019-00611-1; Nakane et al., https://doi.org/10.1080/14737175.2018.1540304	2019; 2018
Quantitative response biomarkers after immunotherapy	In Koay cohort, orthostatic intolerance ratio improved 33.3 [17.8–61.3] → 5.2 [1.4–8.2] (P=.007); HR response to deep breathing 1.5 → 4.5 (P=.02); pupillary constriction 12.0% → 19.0% (P=.02); saliva 0.01 → 0.08 g/min (P=.03); COMPASS-31 52 → 17 (P=.03) (koay2021multimodalbiomarkersquantify pages 1-8, koay2021multimodalbiomarkersquantify media 639533be)	Koay et al., https://doi.org/10.1002/ana.26018	2021
Clinical trial landscape	Very limited prospective evidence; one identified interventional IVIG study: NCT01522235, completed, phase 2/3, enrollment 6 (clinicaltrials.gov result in tool output) (iodice2009efficacyofimmunotherapy pages 1-3)	Beth Israel Deaconess Medical Center trial listing: NCT01522235	—

Table: This table compiles high-yield clinical and mechanistic facts about autoimmune autonomic ganglionopathy, including antibody biology, phenotype frequencies, diagnostics, and treatment patterns. It is designed as a compact evidence summary for rapid knowledge-base ingestion.

Visual evidence from Koay et al. 2021

Figure and tables demonstrating biomarker improvements and immunotherapy regimens are available from the Koay et al. cohort (Figure 2; Tables 4–5). (koay2021multimodalbiomarkersquantify media 639533be, koay2021multimodalbiomarkersquantify media 2579079a, koay2021multimodalbiomarkersquantify media 172ee738)

Notes on evidence limitations

AAG is rare, and much of the treatment evidence base remains small case series or uncontrolled cohorts; even the registered randomized trial (NCT01522235) enrolled only six participants, and outcome numbers were not available in the excerpts retrieved in this run. Population prevalence/incidence and mortality statistics were not found in the retrieved primary sources and should be filled via rare-disease registries/Orphanet or epidemiologic databases if needed for the knowledge base. (NCT01522235 chunk 1, golden2019autoimmuneautonomicneuropathies pages 1-2)

References

(iodice2009efficacyofimmunotherapy pages 1-3): Valeria Iodice, K. Kimpinski, S. Vernino, Paola Sandroni, R. Fealey, and Philip Low. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology, 72:2002-2008, Jun 2009. URL: https://doi.org/10.1212/wnl.0b013e3181a92b52, doi:10.1212/wnl.0b013e3181a92b52. This article has 107 citations and is from a highest quality peer-reviewed journal.
(golden2019autoimmuneautonomicneuropathies pages 1-2): Elisabeth P. Golden and Steven Vernino. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clinical Autonomic Research, 29:277-288, May 2019. URL: https://doi.org/10.1007/s10286-019-00611-1, doi:10.1007/s10286-019-00611-1. This article has 77 citations and is from a peer-reviewed journal.
(nakane2024autoimmuneautonomicneuropathy pages 2-3): Shunya Nakane, Haruki Koike, Tomohiro Hayashi, and Yuji Nakatsuji. Autoimmune autonomic neuropathy: from pathogenesis to diagnosis. International Journal of Molecular Sciences, 25:2296, Feb 2024. URL: https://doi.org/10.3390/ijms25042296, doi:10.3390/ijms25042296. This article has 17 citations.
(koay2021multimodalbiomarkersquantify pages 1-8): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(nakane2024autoimmuneautonomicneuropathy pages 11-12): Shunya Nakane, Haruki Koike, Tomohiro Hayashi, and Yuji Nakatsuji. Autoimmune autonomic neuropathy: from pathogenesis to diagnosis. International Journal of Molecular Sciences, 25:2296, Feb 2024. URL: https://doi.org/10.3390/ijms25042296, doi:10.3390/ijms25042296. This article has 17 citations.
(vernino1998neuronalnicotinicach pages 4-6): Steven Vernino, Jill Adamski, Thomas J. Kryzer, Robert D. Fealey, and Vanda A. Lennon. Neuronal nicotinic ach receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes. Neurology, 50:1806-1813, Jun 1998. URL: https://doi.org/10.1212/wnl.50.6.1806, doi:10.1212/wnl.50.6.1806. This article has 277 citations and is from a highest quality peer-reviewed journal.
(vernino1998neuronalnicotinicach pages 3-4): Steven Vernino, Jill Adamski, Thomas J. Kryzer, Robert D. Fealey, and Vanda A. Lennon. Neuronal nicotinic ach receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes. Neurology, 50:1806-1813, Jun 1998. URL: https://doi.org/10.1212/wnl.50.6.1806, doi:10.1212/wnl.50.6.1806. This article has 277 citations and is from a highest quality peer-reviewed journal.
(nakane2018autoimmuneautonomicganglionopathy pages 6-8): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(vernino1998neuronalnicotinicach pages 1-2): Steven Vernino, Jill Adamski, Thomas J. Kryzer, Robert D. Fealey, and Vanda A. Lennon. Neuronal nicotinic ach receptor antibody in subacute autonomic neuropathy and cancer‐related syndromes. Neurology, 50:1806-1813, Jun 1998. URL: https://doi.org/10.1212/wnl.50.6.1806, doi:10.1212/wnl.50.6.1806. This article has 277 citations and is from a highest quality peer-reviewed journal.
(NCT01522235 chunk 1): Roy Freeman, MD. Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy. Beth Israel Deaconess Medical Center. 2012. ClinicalTrials.gov Identifier: NCT01522235
(loser2024autoantibodiesinneuromuscular pages 13-15): Valentin Loser, Alex Vicino, and Marie Théaudin. Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice. Frontiers in Neurology, Nov 2024. URL: https://doi.org/10.3389/fneur.2024.1495205, doi:10.3389/fneur.2024.1495205. This article has 10 citations and is from a peer-reviewed journal.
(mohapatra2024decodingautoimmuneautonomic pages 4-5): Prachi Mohapatra, Ayush Agarwal, Divya M Radhakrishnan, Achal Kumar Srivastava, and Divyani Garg. Decoding autoimmune autonomic disorders: a less-recognized overlap. Annals of Indian Academy of Neurology, 27:482-492, Oct 2024. URL: https://doi.org/10.4103/aian.aian_394_24, doi:10.4103/aian.aian_394_24. This article has 1 citations and is from a peer-reviewed journal.
(golden2019autoimmuneautonomicneuropathies pages 3-5): Elisabeth P. Golden and Steven Vernino. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clinical Autonomic Research, 29:277-288, May 2019. URL: https://doi.org/10.1007/s10286-019-00611-1, doi:10.1007/s10286-019-00611-1. This article has 77 citations and is from a peer-reviewed journal.
(koay2021multimodalbiomarkersquantify pages 8-13): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(koay2021multimodalbiomarkersquantify pages 13-17): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(koay2021multimodalbiomarkersquantify pages 17-21): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(nakane2018autoimmuneautonomicganglionopathy pages 3-5): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(loser2024autoantibodiesinneuromuscular pages 12-13): Valentin Loser, Alex Vicino, and Marie Théaudin. Autoantibodies in neuromuscular disorders: a review of their utility in clinical practice. Frontiers in Neurology, Nov 2024. URL: https://doi.org/10.3389/fneur.2024.1495205, doi:10.3389/fneur.2024.1495205. This article has 10 citations and is from a peer-reviewed journal.
(iodice2009efficacyofimmunotherapy pages 3-4): Valeria Iodice, K. Kimpinski, S. Vernino, Paola Sandroni, R. Fealey, and Philip Low. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology, 72:2002-2008, Jun 2009. URL: https://doi.org/10.1212/wnl.0b013e3181a92b52, doi:10.1212/wnl.0b013e3181a92b52. This article has 107 citations and is from a highest quality peer-reviewed journal.
(nakane2018autoimmuneautonomicganglionopathy pages 9-10): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(koay2021multimodalbiomarkersquantify media 639533be): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(golden2019autoimmuneautonomicneuropathies pages 5-6): Elisabeth P. Golden and Steven Vernino. Autoimmune autonomic neuropathies and ganglionopathies: epidemiology, pathophysiology, and therapeutic advances. Clinical Autonomic Research, 29:277-288, May 2019. URL: https://doi.org/10.1007/s10286-019-00611-1, doi:10.1007/s10286-019-00611-1. This article has 77 citations and is from a peer-reviewed journal.
(NCT01522235 chunk 2): Roy Freeman, MD. Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy. Beth Israel Deaconess Medical Center. 2012. ClinicalTrials.gov Identifier: NCT01522235
(vernino2009autoimmuneautonomicneuropathy pages 2-4): S Vernino, PA Low, and VA Lennon. Autoimmune autonomic neuropathy. Encyclopedia of Neuroscience, pages 785-789, Jan 2009. URL: https://doi.org/10.1016/b978-008045046-9.00625-2, doi:10.1016/b978-008045046-9.00625-2. This article has 1 citations.
(nakane2024autoimmuneautonomicneuropathy pages 12-14): Shunya Nakane, Haruki Koike, Tomohiro Hayashi, and Yuji Nakatsuji. Autoimmune autonomic neuropathy: from pathogenesis to diagnosis. International Journal of Molecular Sciences, 25:2296, Feb 2024. URL: https://doi.org/10.3390/ijms25042296, doi:10.3390/ijms25042296. This article has 17 citations.
(nakane2018autoimmuneautonomicganglionopathy pages 1-3): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(nakane2018autoimmuneautonomicganglionopathy pages 5-6): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(nakane2018autoimmuneautonomicganglionopathy pages 8-9): Shunya Nakane, Akihiro Mukaino, Osamu Higuchi, Mari Watari, Yasuhiro Maeda, Makoto Yamakawa, Keiichi Nakahara, Koutaro Takamatsu, Hidenori Matsuo, and Yukio Ando. Autoimmune autonomic ganglionopathy: an update on diagnosis and treatment. Expert Review of Neurotherapeutics, 18:953-965, Nov 2018. URL: https://doi.org/10.1080/14737175.2018.1540304, doi:10.1080/14737175.2018.1540304. This article has 42 citations and is from a peer-reviewed journal.
(koay2021multimodalbiomarkersquantify media 2579079a): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.
(koay2021multimodalbiomarkersquantify media 172ee738): Shiwen Koay, Ekawat Vichayanrat, Fion Bremner, Jalesh N. Panicker, Bethan Lang, Michael P. Lunn, Laura Watson, Gordon T. Ingle, Ellen Merete Hagen, Patricia McNamara, Leslie Jacobson, Vincenzo Provitera, Maria Nolano, Angela Vincent, Christopher J. Mathias, and Valeria Iodice. Multimodal biomarkers quantify recovery in autoimmune autonomic ganglionopathy. Annals of Neurology, 89:753-768, Feb 2021. URL: https://doi.org/10.1002/ana.26018, doi:10.1002/ana.26018. This article has 30 citations and is from a highest quality peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Mappings

Definitions

Subtypes

Pathophysiology

Pathograph

Phenotypes

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)

Autoimmune Autonomic Ganglionopathy (AAG) — Comprehensive Disease Characteristics Report

Executive summary

1. Disease information

1.1 Definition and current understanding

1.2 Synonyms / alternative names

1.3 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

1.4 Evidence sources

2. Etiology

2.1 Primary causal factors (mechanistic)

2.2 Risk factors

2.3 Protective factors / gene–environment interactions

3. Phenotypes

3.1 Core clinical phenotype (multi-domain autonomic failure)

3.2 Suggested HPO terms (non-exhaustive; map to patient-level data when available)

3.3 Quality of life impact

4. Genetic / molecular information

4.1 Causal genes

4.2 Pathogenic “variants”

4.3 Epigenetics / modifiers

5. Environmental information

5.1 Infectious or other triggers

6. Mechanism / pathophysiology

6.1 Causal chain (antibody-mediated archetype)

6.2 Upstream vs downstream processes

6.3 Cell types and GO / CL suggestions

6.4 Molecular profiling / multi-omics

7. Anatomical structures affected

7.1 Organ and system level

7.2 Subcellular / receptor localization

8. Temporal development

8.1 Onset

8.2 Course and progression

9. Inheritance and population

9.1 Epidemiology

9.2 Demographics

10. Diagnostics

10.1 Core diagnostic concept

10.2 Antibody testing: assays and interpretation

10.3 Autonomic testing and ancillary diagnostics

10.4 Differential diagnosis

11. Outcome / prognosis

12. Treatment

12.1 Immunotherapy (disease-modifying)

12.2 Symptomatic/supportive care (real-world implementations)

12.3 Clinical trials

12.4 Suggested MAXO terms (non-exhaustive)

13. Prevention

14. Other species / natural disease

15. Model organisms

Recent developments (prioritizing 2023–2024)

Diagnostics and assay technology

Phenotyping and biomarkers for treatment response

Expert opinions / authoritative analysis (from reviews)

Key quantitative statistics (selected)

Evidence table (compact)

Visual evidence from Koay et al. 2021

Notes on evidence limitations

Artifacts